Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas

Endocrine Journal

Volumn 59, Issue 3, 2012, Pages 221-228

  Kato, Masako ^a   Inoshita, Naoko ^b   Sugiyama, Toru ^a   Tani, Yuji ^a   Shichiri, Masayoshi ^c   Sano, Toshiaki ^d   Yamada, Shozo ^b   Hirata, Yukio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d 2 24 18 Higashikoiwa   (Japan)

Author keywords

Drug responsiveness; Growth hormone secreting pituitary adenoma; Real time RT PCR; SSTR2

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; GROWTH HORMONE; MESSENGER RNA; OCTREOTIDE; PARODEL; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER INVASION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSELY GRANULATED SOMATOTROPH ADENOMA; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPARSELY GRANULATED SOMATOTROPH ADENOMA; TUMOR CLASSIFICATION; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGE FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MALE; MIDDLE AGED; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES;

EID: 84859069728     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0177     Document Type: Article

References (23)

1. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M (1995) Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 80: 3395-3402.
2. Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, Takada K (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33: 20-27.
3. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133: 686-690.
4. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19: 82-91.
5. Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, Inoshita N, Oyama K, Yamada S, Hirata Y (2007) Differential gene expression in ACTH-secreting and non-functioning pituitary tumors. Eur J Endocrinol 157: 717-724.
6. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87: 4554-4563.
7. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Longterm effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86: 2779-2786.
8. Bruns C, Raulf F, Hoyer D, Schloos J, Lubbert H, Weckbecker G (1996) Binding properties of somatostatin receptor subtypes. Metabolism 45: 17-20.
9. Culler MD, Taylor JE, Moreau JP (2002) Somatostatin receptor subtypes: targeting functional and therapeutic specificity. Ann Endocrinol (Paris) 63: 2S5-12.
10. Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K, Hoyer D (2002) Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci 18: 15-27.
11. Osapay G, Prokai L, Kim HS, Medzihradszky KF, Coy DH, Liapakis G, Reisine T, Melacini G, Zhu Q, Wang SH, Mattern RH, Goodman M (1997) Lanthioninesomatostatin analogs: synthesis, characterization, bio-logical activity, and enzymatic stability studies. J Med Chem 40: 2241-2251.
12. Reisine T, Bell GI (1995) Molecular biology of somatostatin receptors. Endocr Rev 16: 427-442.
13. Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79: 724-729.
14. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80: 1386-1392.
15. Bertherat J, Chanson P, Dewailly D, Dupuy M, Jaquet P, Peillon F, Epelbaum J (1993) Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas. J Clin Endocrinol Metab 77: 1577-1583.
16. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 93: 1412-1417.
17. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH (2000) Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85: 781-792.
18. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P (2001) Bim-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotideresistant human GH-secreting adenomas. J Clin Endocrinol Metab 86: 140-145.
19. Barlier A, Zamora AJ, Grino M, Gunz G, Pellegrini-Bouiller I, Morange-Ramos I, Figarella-Branger D, Dufour H, Jaquet P, Enjalbert A (1999) Expression of functional growth hormone secretagogue receptors in human pituitary adenomas: polymerase chain reaction, triple in-situ hybridization and cell culture studies. J Neuroendocrinol 11: 491-502.
20. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P (2006) Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83: 258-263.
21. Pellegrini I, Costa R, Grisoli F, Jaquet P (1989) Abnormal dopamine sensitivity in some human prolactinomas. Horm Res 31: 19-23.
22. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U (2007) Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 19: 2304-2316.
23. Ferone D, Saveanu A, Culler MD, Arvigo M, Rebora A, Gatto F, Minuto F, Jaquet P (2007) Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 156 Suppl 1: S23-28.